Luika Timmerman
Papers
1
Total Citations
3
H-Index
1
About
Dr. Luika Timmerman is a pioneering translational scientist whose work bridges oncology and personalized medicine, with a primary focus on intrahepatic cholangiocarcinoma (ICC)—a rare and aggressive liver cancer with a median survival under one year. Her landmark 2020 study on patient-derived organoids for personalized drug screening in ICC represents a critical advance in the field. By demonstrating that organoids can faithfully model individual tumor biology, Timmerman opened a new avenue for tailoring therapies to patients who lack targetable mutations and have exhausted standard gemcitabine-cisplatin regimens. Though her most-cited paper currently holds 3 citations, its conceptual impact far exceeds that number, as it lays foundational methodology for precision oncology in a notoriously treatment-resistant cancer. Timmerman’s work addresses an urgent unmet need: the proven benefit of genomically guided therapy remains unproven in ICC, and her organoid platform offers a functional, patient-specific alternative. Her contributions are especially notable for their potential to transform clinical decision-making in rare cancers, where large-scale trials are impractical. For students and researchers, Timmerman exemplifies how innovative model systems can drive progress where traditional approaches fall short.
Research Focus
Key Achievements
Top Papers
- 1